Tellgen(SZ:300642) Xin Lang Cai Jing·2025-09-16 03:00Core Viewpoint - The stock of TuoJing Life has experienced significant fluctuations, with a year-to-date increase of 88.23%, indicating strong market interest despite recent declines in share price and financial performance [1][2]. Financial Performance - For the first half of 2025, TuoJing Life reported revenue of 159 million yuan, a year-on-year decrease of 26.25%, and a net profit attributable to shareholders of 2.76 million yuan, down 58.41% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 264 million yuan, with 81.36 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 16, TuoJing Life's stock price was 26.30 yuan per share, with a market capitalization of 4.275 billion yuan. The stock has seen a trading volume of 96.61 million yuan and a turnover rate of 2.63% [1]. - The stock has experienced a net outflow of 2.24 million yuan in principal funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for TuoJing Life was 16,000, a decrease of 6.19% from the previous period, while the average number of circulating shares per person increased by 6.60% to 8,614 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A is a new entrant, holding 1.20 million shares [3]. Business Overview - TuoJing Life, established on November 6, 2003, and listed on April 21, 2017, specializes in the research, production, and sales of in vitro diagnostic products, with 92.50% of its revenue coming from reagent sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics [1].